NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research,…
2 analysts rate NBP Buy on consensus.
Consensus price target: $9.00 (+791.09% upside from $1.01)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Cao Sean Wuxiong Chief Bus. Development Officer | Sep 9, 2026 | Sale | 107,978 | $79.9K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-6.61M |
| 2024 | $0 | -100% | $-24.33M |
| 2023 | $672.74K | +141.93% | $-219.81M |
Stock data for NBP: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics